Indicated for the treatment of:

• Differentiated Thyroid Cancer (DTC): single agent for patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory DTC.
• Renal Cell Cancer (RCC): in combination with everolimus, for patients with advanced RCC following one prior anti-angiogenic therapy.

4 mg and 10 mg Capsules

Recommended dose:

• • Differentiated Thyroid Cancer
    • 24 mg orally, once daily
  • Renal Cell Cancer
    • 18 mg LENVIMA + 5 mg everolimus, orally, once daily

In patients with severe renal or hepatic impairment, the dose is 14 mg once daily in DTC and 10 mg once daily in RCC.

EMA approved in June 2015; FDA approved in February 2015

Registered in Kuwait

Under registration in GCC